Seres Therapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company focused on developing microbiome therapeutics to treat medically important diseases through the restoration, stabilization, and enhancement of the human microbiome. The company develops and commercializes investigational oral live biotherapeutic products, including VOWST (fecal microbiota spores, live-brpk), an FDA-approved therapy for the prevention of Clostridioides difficile (C. diff) infection recurrence in adults following antibiotic treatment; SER-109, an oral capsule formulation of Firmicutes spores for the same indication; SER-155, an oral live biotherapeutic targeting enteric pathogens for patients undergoing allogeneic hematopoietic stem cell transplantation; and SER-155CT, a variant designed to reduce infection risk and graft-versus-host disease in similar patients, along with earlier-stage candidates like SER-344 for inflammatory bowel disease and SER-382 for food allergy. Seres operates primarily in the United States, with research and development activities centered on its Cambridge, Massachusetts headquarters, where the company was founded in 2010. In recent developments within the last two years, Seres completed the commercial launch of VOWST in 2023 following FDA approval, entered into a strategic collaboration with Nestlé Health Science to co-promote VOWST and expand commercialization efforts, reported positive Phase 3 data for SER-109 leading to supplemental Biologics License Application submission, and advanced SER-155 into clinical studies amid ongoing funding through equity offerings and partnerships to support its pipeline expansion in infectious diseases and immunotherapy.
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Seres Therapeutics to Present at CARB-X Investor Day
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks Transcript
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average – Time to Sell?
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average – Time to Sell?
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving Average – Here’s What Happened
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference